Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation. The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised treatment plans for the treatment and management of the anti-synthetic enzyme complex accompanying the synthetic antibodies are usually included in drug therapy, convalescence, regular follow-up, and multi-dimensional management.
In recent years, with the development of therapeutic-focused, immune-regulatory therapies and precision medicine, many previously difficult to treat autoimmune and rheumatic immune disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of semisynthetic antibodies associated with synthetase syndrome.
The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3.
Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.